What drugs does UPJOHN make?

UPJOHN has 12 FDA-approved drugs including LYRICA CR.

What therapeutic areas does UPJOHN focus on?

UPJOHN focuses primarily on Neurology and Cardiovascular and 1 other therapeutic areas.

Data updated: Mar 10, 2026

UPJOHN

NeurologyCardiovascularMetabolic

Big Pharma

UPJOHN is a major pharmaceutical company focused on Neurology, Cardiovascular, Metabolic. Key products include LYRICA CR.

1981

Since

Drugs

Trials

Approved (2yr)

Key Drugs

LYRICA CR

pregabalin

Pain

alpha 2 ‑delta subunit of voltage‑gated calcium channels 3 indications · 2017

Recent Activity

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 38%

3 drugs

Cardiovascular 25%

2 drugs

Metabolic 13%

1 drugs

Immunology 13%

1 drugs

Ophthalmology 13%

1 drugs

Pipeline Strength ProEarly access

Competitors ProEarly access

Novartis big-pharma

Cardiovascular, Immunology, Ophthalmology

Merck big-pharma

Cardiovascular, Immunology, Metabolic

AbbVie big-pharma

Immunology, Neurology, Ophthalmology

Johnson & Johnson big-pharma

Immunology, Cardiovascular, Metabolic

Eli Lilly big-pharma

Metabolic, Immunology, Neurology

UPJOHN

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (12)

Active (11)

Discontinued (1)

Company Info